Novartis

Latest articles

1d
New York Daily News
Procter & Gamble agrees to add activist investor to boardsupport, he will be given a seat on the board starting March 1. Joseph Jimenez,
New York Daily News / Posted yesterday
support, he will be given a seat on the board starting March 1. Joseph Jimenez, the CEO of pharmaceutical company Novartis, was also added to the board. Peltz's Trian Fund Management owns about $3.5 billion in P&G shares and has urged the... Read more
6 related articles
1d
The Courier Express Newspapers
Procter & Gamble agrees to add activist investor to boardsupport, he will be given a seat on the board starting March 1. Joseph Jimenez,
The Courier Express Newspapers / Posted yesterday
support, he will be given a seat on the board starting March 1. Joseph Jimenez, the CEO of pharmaceutical company Novartis, was also added to the board. Peltz's Trian Fund Management owns about $3.5 billion in P&G shares and has urged the... Read more
6 related articles
1d
WPXI Pittsburgh
Procter & Gamble agrees to add activist investor to boardsupport, he will be given a seat on the board starting March 1. Joseph Jimenez,
WPXI Pittsburgh / Posted yesterday
support, he will be given a seat on the board starting March 1. Joseph Jimenez, the CEO of pharmaceutical company Novartis, was also added to the board. Peltz's Trian Fund Management owns about $3.5 billion in P&G shares and has urged the... Read more
6 related articles
1d
Fortune
P&G Just Appointed Activist Investor Nelson Peltz to Board Following Proxy Battleit increased its board size by 2 to 13—to accommodate Peltz and appoint a new d
Fortune / Posted yesterday
it increased its board size by 2 to 13—to accommodate Peltz and appoint a new director in Joseph Jimenez, CEO of drugmaker Novartis. P&G said it had recounted nearly two billion votes, many of which were paper ballots. The recount showed that... Read more
6 related articles
1d
Daily Herald
Procter & Gamble agrees to add activist investor to boardsupport, he will be given a seat on the board starting March 1. Joseph Jimenez,
Daily Herald / Posted yesterday
support, he will be given a seat on the board starting March 1. Joseph Jimenez, the CEO of pharmaceutical company Novartis, was also added to the board. Peltz's Trian Fund Management owns about $3.5 billion in P&G shares and has urged the... Read more
6 related articles
1d
ABC 7 Gulfshore News
Procter & Gamble agrees to add activist investor to boardsupport, he will be given a seat on the board starting March 1. Joseph Jimenez,
ABC 7 Gulfshore News / Posted yesterday
support, he will be given a seat on the board starting March 1. Joseph Jimenez, the CEO of pharmaceutical company Novartis, was also added to the board. Peltz's Trian Fund Management owns about $3.5 billion in P&G shares and has urged the... Read more
6 related articles
1d
WFMZ Eastern Pennsylvania and Western New Jersey
Procter & Gamble agrees to add activist investor to boardsupport, he will be given a seat on the board starting March 1. Joseph Jimenez,
WFMZ Eastern Pennsylvania and Western New Jersey / Posted yesterday
support, he will be given a seat on the board starting March 1. Joseph Jimenez, the CEO of pharmaceutical company Novartis, was also added to the board. Peltz's Trian Fund Management owns about $3.5 billion in P&G shares and has urged the... Read more
6 related articles
1d
Zero Hedge
Proctor & Gamble Concedes Proxy Fight, Names Nelson Peltz To Boardon excessive leverage, substantially reduce R&D spending or break up the compan
Zero Hedge / Posted yesterday
on excessive leverage, substantially reduce R&D spending or break up the company. In addition, P&G said it would also add Novartis AG Chief Executive Joseph Jimenez to its board on March 1. P&G is the biggest U.S. company by market value to face... Read more
2d
FOX Business
ASH 2017 Recap: These Were the Big Winners and Losersthe expertise to make them, particularly given the huge demand because of this
FOX Business / Posted 2 days ago
the expertise to make them, particularly given the huge demand because of this surge in gene-therapy research. For example, Novartis signed a contract years ago with Oxford BioMedica just to give them the right to get these viruses for their... Read more
2d
FOX Business
ASH 2017 Recap: These Were the Big Winners and Losersthe expertise to make them, particularly given the huge demand because of this
FOX Business / Posted 2 days ago
the expertise to make them, particularly given the huge demand because of this surge in gene-therapy research. For example, Novartis signed a contract years ago with Oxford BioMedica just to give them the right to get these viruses for their... Read more
2d
San Francisco Chronicle
Patients die as Gilead’s breakthrough cancer drug reaches only a fewGilead’s manufacturing plants to make them capable of attacking tumors, and re-
San Francisco Chronicle / Posted 2 days ago
Gilead’s manufacturing plants to make them capable of attacking tumors, and re-infusing them into the person. Yescarta and Novartis’ Kymriah were only approved in the last several months. Because CAR-Ts are so new — and because the one-time... Read more
2d
San Francisco Chronicle
Patients die as breakthrough Gilead cancer drug reaches only a fewGilead's manufacturing plants to make them capable of attacking tumors, and re-
San Francisco Chronicle / Posted 2 days ago
Gilead's manufacturing plants to make them capable of attacking tumors, and re-infusing them into the person. Yescarta and Novartis's Kymriah were only approved in the last several months. Because CAR-Ts are so new -- and because the one-time,... Read more
3d
Channel NewsAsia
Bumper crop of new drugs fails to lift big pharma R&D returnsof cancer. A few are truly ground-breaking, such as the first gene-modified ce
Channel NewsAsia / Posted 3 days ago
of cancer. A few are truly ground-breaking, such as the first gene-modified cell therapy against a type of leukemia from Novartis, and next year is expected to see the first U.S. approval of a gene therapy for a rare inherited eye... Read more
3d
FOX Business
Novartis generics arm says may sell or end some productsZURICH (Reuters) - Swiss drugmaker Novartis's Sandoz generics business is in th
FOX Business / Posted 3 days ago
ZURICH (Reuters) - Swiss drugmaker Novartis's Sandoz generics business is in the process of selling or closing some products in the United States, it said on Wednesday. "In response to high price pressure, we are optimizing our U.S. portfolio. This... Read more
2 related articles
3d
FOX Business
Novartis generics arm says may sell or end some productsZURICH (Reuters) - Swiss drugmaker Novartis's Sandoz generics business is in th
FOX Business / Posted 3 days ago
ZURICH (Reuters) - Swiss drugmaker Novartis's Sandoz generics business is in the process of selling or closing some products in the United States, it said on Wednesday. Continue Reading Below "In response to high price pressure, we are optimizing... Read more
2 related articles
3d
Channel NewsAsia
Novartis generics arm says may sell or end some productsZURICH: Swiss drugmaker Novartis's Sandoz generics business is in the process o
Channel NewsAsia / Posted 3 days ago
ZURICH: Swiss drugmaker Novartis's Sandoz generics business is in the process of selling or closing some products in the United States, it said on Wednesday. "In response to high price pressure, we are optimizing our U.S. portfolio. This includes... Read more
2 related articles
3d
Newsweek
Trump, tasty pigs and hurricanes: The top medical stories of the yeara gene therapy to treat acute lymphoblastic leukemia in children and young adul
Newsweek / Posted 3 days ago
a gene therapy to treat acute lymphoblastic leukemia in children and young adults. Manufactured by pharmaceutical company Novartis, Kymriah is a novel cancer treatment known broadly as CAR-T therapy. In the treatment, a patient’s T-cells (the... Read more
4d
Fremont Tribune
Letter: Alzheimer's studyGeneration Study will involve 80 sites, it's lead by the Phoenix based Bahner A
Fremont Tribune / Posted 4 days ago
Generation Study will involve 80 sites, it's lead by the Phoenix based Bahner Alzheimer's Institute and drug makers Novartis and Amgen. To quote Dr. Murman, "We are much more optimistic we'll be more successful at the earlier stage." And Dr.... Read more
4d
AllAfrica.com
Heart Failure - the Leading Cause of Death in New Mothers From Northern Nigeria?delivery in young women) was one of the issues discussed at the just concluded
AllAfrica.com / Posted 4 days ago
delivery in young women) was one of the issues discussed at the just concluded Heart Failure awareness event, supported by Novartis on the 24th of November, 2017. Consultant cardiologists from all over Nigeria and several representatives from media... Read more
5d
Colorado Daily
A good fight: Cancer 'like a moss' and a young Lafayette girl's journey through itused in children, according to the NIH. The "poster child" is imatinib, develop
Colorado Daily / Posted 5 days ago
used in children, according to the NIH. The "poster child" is imatinib, developed in 2001 by Swiss pharmaceutical giant Novartis and marketed as Gleevec. Gleevec boosted the chances of survival from less than one in three to over 90 percent for... Read more
5d
Swissinfo
Life-Shortening Blood Disease Gets Rush of Gene-Based Researcha pill taken five times a day, reduced anemia and pain in a trial of 11 teenage
Swissinfo / Posted 5 days ago
a pill taken five times a day, reduced anemia and pain in a trial of 11 teenagers presented at ASH. And Novartis AG’s crizanlizumab, an antibody infused in the body, also delayed the onset of pain. The excitement about gene... Read more
5d
Business Standard India
Indian pharma companies under pressure on bourses, MNC peers fare bettera combination of measles, mumps, rubella and varicella vaccine in the quarter.
Business Standard India / Posted 5 days ago
a combination of measles, mumps, rubella and varicella vaccine in the quarter. Earlier, it acquired distribution rights for Novartis’ vaccine portfolio, including Rabipur, which also bodes well. Amongst other initiatives, GSK launched Entero... Read more
6d
FOX Business
You'll Be Stunned by How Many Cancer Immunotherapies Are Being Developed224 clinical-stage cell therapy I-O drugs. Cell therapy involves putting cellul
FOX Business / Posted 6 days ago
224 clinical-stage cell therapy I-O drugs. Cell therapy involves putting cellular material into a patient to fight cancer. Novartis' (NYSE: NVS) Kymriah became the first cell therapy to win regulatory approval in August for treatment of B-cell... Read more
6d
FOX Business
You'll Be Stunned by How Many Cancer Immunotherapies Are Being Developed224 clinical-stage cell therapy I-O drugs. Cell therapy involves putting cellul
FOX Business / Posted 6 days ago
224 clinical-stage cell therapy I-O drugs. Cell therapy involves putting cellular material into a patient to fight cancer. Novartis' (NYSE: NVS) Kymriah became the first cell therapy to win regulatory approval in August for treatment of B-cell... Read more
6d
Channel NewsAsia
'Unheard of' responses to bluebird CAR-T therapy seen in myeloma studyso they can circulate seeking out and attacking the cancer, possibly for years.
Channel NewsAsia / Posted 6 days ago
so they can circulate seeking out and attacking the cancer, possibly for years. The first two CAR-T therapies from Novartis and Gilead Sciences, through its acquisition of Kite Pharma, were approved earlier this year for other blood... Read more
6d
Channel NewsAsia
Novartis CAR-T therapy leads to durable response in lymphoma studyREUTERS: Patients with an advanced form of an aggressive blood cancer who had i
Channel NewsAsia / Posted 6 days ago
REUTERS: Patients with an advanced form of an aggressive blood cancer who had initially responded to Novartis' new type of gene-modifying immunotherapy continued to respond at least six months after treatment, according to updated data released at a... Read more
8d
The Holmes Report
Novartis Ushers In New Comms Approach With Holding Group Consolidation NEW YORK — Healthcare giant Novartis is ushering in sweeping changes to its glo
The Holmes Report / Posted 8 days ago
NEW YORK — Healthcare giant Novartis is ushering in sweeping changes to its global communications approach, consolidating the bulk of its lucrative agency activity with three holding groups, the Holmes Report can reveal. The decision follows a... Read more
8d
Swissinfo
A Swiss Startup Is Pumping Out Legal Hashishmodern pharmaceutical sector, which was spawned from the country’s dye and chem
Swissinfo / Posted 8 days ago
modern pharmaceutical sector, which was spawned from the country’s dye and chemical makers. Drug-making giants Roche and Novartis call the Alpine nation home. Now a Swiss startup is blazing a fresh path by bringing a different kind of drug to... Read more
9d
WA Today
Aussie fans call on Calvin Harris to keep bizarre promise following same-sex marriage billsues Voltaren for misleading consumers The Australian Competition and Consumer
WA Today / Posted 9 days ago
sues Voltaren for misleading consumers The Australian Competition and Consumer Commission is taking GlaxoSmithKline and Novartis to the Federal Court, alleging the pharmaceutical companies made false or misleading marketing claims about Voltaren... Read more
10 related articles
9d
KFVS 12 Cape Girardeau
New breast cancer drug may benefit younger women, toocautioned, though, that Kisqali is not yet approved for premenopausal women. L
KFVS 12 Cape Girardeau / Posted 9 days ago
cautioned, though, that Kisqali is not yet approved for premenopausal women. Last month, Kisqali's maker Novartis said it would "begin discussions" with drug regulators based on these trial results. Tripathy, who is a paid... Read more
9d
Australian Broadcasting Corporation
Chances are your tax rate is higher than every company in AustraliaLIMITED573,886,12627,863,3314,136,0761%15%HONAN HOLDINGS PTY LIMITED1,194,205,9
Australian Broadcasting Corporation / Posted 9 days ago
LIMITED573,886,12627,863,3314,136,0761%15%HONAN HOLDINGS PTY LIMITED1,194,205,99524,627,4553,738,2340.3%15%NOVARTIS AUSTRALIA PTY LIMITED1,142,036,36267,803,55310,292,2991%15%BOMBARDIER TRANSPORTATION AUSTRALIA PTY... Read more
10d
B&T
Vevo's Nic Jones Joins Pureprofile As CEOConsumer Commission (ACCC) has instituted Federal Court proceedings against Gla
B&T / Posted 10 days ago
Consumer Commission (ACCC) has instituted Federal Court proceedings against GlaxoSmithKline Healthcare Australia (GSK) and Novartis Consumer Health Australasia (Novartis), alleging they made false or misleading representations in the marketing of... Read more
10 related articles
10d
Mumbrella
ACCC accuses Voltaren manufacturers of 'misleading representations' in marketing messagesThe Australian Competition and Consumer Commission (ACCC) watchdog has initiate
Mumbrella / Posted 10 days ago
The Australian Competition and Consumer Commission (ACCC) watchdog has initiated legal proceedings against GSK and Novartis alleging the drug companies made “false or misleading representations” in the marketing of its Voltaren Osteo Gel and Voltaren... Read more
10 related articles
10d
Op-Ed News
Beware These Pharma Dirty TricksCitizen's Health Research Group. Thirty-one major drug companies to date includ
Op-Ed News / Posted 10 days ago
Citizen's Health Research Group. Thirty-one major drug companies to date including Pfizer, Eli Lilly, Johnson & Johnson, Novartis, Forest, Amgen and Allergan, have entered into settlements for "off-label marketing"----selling their drugs for any... Read more
10d
PRWeek US
PRWeek U.S. Awards 2018 shortlist revealedand Golin: McDonald's theSTRAW MET-Rx and MWWPR: Greater Than Gold: NFL Rookie
PRWeek US / Posted 10 days ago
and Golin: McDonald's theSTRAW MET-Rx and MWWPR: Greater Than Gold: NFL Rookie & MET-Rx Mold Future Athletes Novartis Pharma AG and Creation: MS: No FilterOutstanding Young Professional Sponsored by General Motors Amberly Asay,... Read more
10d
Business Wire
Tango Therapeutics Announces the Addition of Shakti Narayan, Ph.D., J.D. as Chief Business OfficerPh.D., has joined the company as Vice President of Operations, Program and Port
Business Wire / Posted 10 days ago
Ph.D., has joined the company as Vice President of Operations, Program and Portfolio Management. Dimitris joins Tango from Novartis Oncology, where he worked most recently in oncology business development and licensing roles. In addition, Tania... Read more
10d
Canberra Times
ACCC sues Voltaren makers GlaxoSmithKline and Novartis for misleading consumersrelief", when this was not the case. The Australian Competition and Consumer h
Canberra Times / Posted 10 days ago
relief", when this was not the case. The Australian Competition and Consumer has launched court action against GSK and Novartis, accusing the pair of making misleading claims about Voltaren Osteo Gel and Voltaren Emulgel, which have the... Read more
10 related articles
11d
AllAfrica.com
Hope for Cancer Patients As Uganda Gets New Machineservices, doctors at the cancer institute will now have the ability to reach mo
AllAfrica.com / Posted 11 days ago
services, doctors at the cancer institute will now have the ability to reach more patients. In addition to telepathology for Uganda, ACS and ASCP will work with Novartis to provide immunohistochemistry analysis to hospitals in Ethiopia and Tanza... Read more
11d
citybizlist Dallas
The 30 Largest Companies on the Stock Marketin the company in March of 2009 and held their shares has seen a fourfold retur
citybizlist Dallas / Posted 11 days ago
in the company in March of 2009 and held their shares has seen a fourfold return on their investment. IMAGE SOURCE: NOVARTIS.30. Novartis Another Swiss pharmaceutical company on the list, Novartis AG (ADR) (NYSE:NVS) rounds out the top 30... Read more
11d
TheBull
Australia takes GSK, Novartis to court over 'misleading' claimsDrug giants GlaxoSmithKline and Novartis are being taken to court by Australia'
TheBull / Posted 11 days ago
Drug giants GlaxoSmithKline and Novartis are being taken to court by Australia's consumer watchdog over "false or misleading" claims in the marketing of pain relief products, it was announced Wednesday. 06.12.2017 04:44 PM Drug giants... Read more
10 related articles
11d
Australian Broadcasting Corporation
Drug companies accused of 'misleading' consumers over pain cream: ACCCregular Voltaren. Key points: Australian Competition and Consumer Commission
Australian Broadcasting Corporation / Posted 11 days ago
regular Voltaren. Key points: Australian Competition and Consumer Commission (ACCC) is taking GlaxoSmithKline (GSK) and Novartis to the Federal Court, alleging the companies were "false or misleading" in marketing Voltaren Osteo Gel and Voltaren... Read more
10 related articles
11d
Swissinfo
Nestle to Buy Supplements Maker Atrium for $2.3 Billionnutrition since the company accelerated its push into health in 2006 by spendin
Swissinfo / Posted 11 days ago
nutrition since the company accelerated its push into health in 2006 by spending about $2.5 billion on businesses from Novartis AG that made food for hospital patients. “This is a good start,” said Jon Cox, an analyst at Kepler Cheuvreux in... Read more
4 related articles
11d
Business Wire
Sunovion Receives FDA Approval for Lonhala™ Magnair™ Inhalation Solution to Treat COPDPharmaceuticals Inc. APTIOM is a registered trademark of BIAL, used under lice
Business Wire / Posted 11 days ago
Pharmaceuticals Inc. APTIOM is a registered trademark of BIAL, used under license. SEEBRI and UTIBRON are trademarks of Novartis AG, used under license. ARCAPTA and NEOHALER are registered trademarks of Novartis AG, used under license. LONHALA... Read more
11d
Boston Globe
Netherlands puts drug makers on notice about high pricesto thwart such moves, which is what happened last year when Colombia’s health m
Boston Globe / Posted 11 days ago
to thwart such moves, which is what happened last year when Colombia’s health minister threatened to issue a license for a Novartis cancer drug. In that instance, the company and government haggled over the price of Gleevec. Failing to reach... Read more
11d
WA Today
ACCC sues Voltaren makers GlaxoSmithKline and Novartis for misleading consumersThe consumer watchdog is taking GlaxoSmithKline and Novartis to the Federal Cou
WA Today / Posted 11 days ago
The consumer watchdog is taking GlaxoSmithKline and Novartis to the Federal Court, alleging the global pharma giants misled consumers about their Voltaren Osteo Gel and Voltaren Emulgel pain relief products. GSK and Novartis marketed Osteo Gel as a... Read more
10 related articles
11d
Sydney Morning Herald
ACCC sues Voltaren makers GlaxoSmithKline and Novartis for misleading consumersThe consumer watchdog is taking GlaxoSmithKline and Novartis to the Federal Cou
Sydney Morning Herald / Posted 11 days ago
The consumer watchdog is taking GlaxoSmithKline and Novartis to the Federal Court, alleging the global pharma giants misled consumers about their Voltaren Osteo Gel and Voltaren Emulgel pain relief products. GSK and Novartis marketed Osteo Gel as a... Read more
10 related articles
11d
The Age
ACCC sues Voltaren makers GlaxoSmithKline and Novartis for misleading consumersThe consumer watchdog is taking GlaxoSmithKline and Novartis to the Federal Cou
The Age / Posted 11 days ago
The consumer watchdog is taking GlaxoSmithKline and Novartis to the Federal Court, alleging the global pharma giants misled consumers about their Voltaren Osteo Gel and Voltaren Emulgel pain relief products. GSK and Novartis marketed Osteo Gel as a... Read more
10 related articles
11d
The Courier Mail
Consumers 'misled by Voltaren advertising'Australian Competition and Consumer Commission alleges the local divisions of U
The Courier Mail / Posted 11 days ago
Australian Competition and Consumer Commission alleges the local divisions of UK firm GlaxoSmithKline and Switzerland's Novartis advertised Voltaren Osteo Gel - which Novartis sold to Glaxo in 2016 - as particularly suitable for osteoarthritis... Read more
10 related articles
11d
News.com.au
Consumers ‘misled by Voltaren advertising’Australian Competition and Consumer Commission alleges the local divisions of U
News.com.au / Posted 11 days ago
Australian Competition and Consumer Commission alleges the local divisions of UK firm GlaxoSmithKline and Switzerland's Novartis advertised Voltaren Osteo Gel - which Novartis sold to Glaxo in 2016 - as particularly suitable for osteoarthritis... Read more
11d
Channel NewsAsia
Australian watchdog takes GlaxoSmithKline, Novartis units to courtand Consumer Commission (ACCC) on Wednesday said it is taking local units of Gl
Channel NewsAsia / Posted 11 days ago
and Consumer Commission (ACCC) on Wednesday said it is taking local units of GlaxoSmithKline and Swiss healthcare company Novartis to court over false or misleading representations in the marketing of pain relief products. The ACCC alleged that... Read more
10 related articles
More

In this news